MIC / Lipotropic Injection (Methionine / Inositol / Choline)

Also known as: MIC injection, lipotropic injection, Lipo-MIC, fat-burner shot

IM / IV / SQ TherapyWeight Management

In plain English

MIC (methionine, inositol, choline) "lipotropic" injections — often combined with B12 and carnitine — are marketed as "fat-burner shots" to support weight loss and liver fat metabolism. Each ingredient has a real role in how the body handles fats and methyl groups, and correcting a genuine choline deficiency helps the liver. But there are no good controlled trials showing that MIC injections themselves cause weight loss in well-nourished people, so the fat-loss claim is not evidence-based. They are compounded, not FDA-approved.

The science

The lipotropic rationale is that choline is required to make phosphatidylcholine for hepatic VLDL export (choline deficiency causes fatty liver, reversible on repletion; Zeisel, Nutr Rev 2009), methionine feeds S-adenosylmethionine/transsulfuration and methylation (Lu & Mato, 2012), and inositol has insulin-sensitizing signaling roles (with mixed RCT evidence, e.g., in PCOS; Fitzgerald et al., 2023). However, these are physiologic roles in deficiency or specific conditions, not evidence that combined MIC (± B12/carnitine) injections produce weight loss in replete individuals — no adequately controlled trials support the "fat-burner" use. These are compounded products, not FDA-approved; components are generally well tolerated. (See also methylcobalamin_b12 and l_carnitine entries.)

References

• Zeisel SH, da Costa KA, Nutr Rev 2009 (Choline: an essential nutrient for public health)
• Mato JM et al., Ann Hepatol 2013 (S-adenosylmethionine/methionine metabolism and liver disease)
• Fitzgerald S et al., J Clin Endocrinol Metab 2024 (inositol for PCOS meta-analysis; benefit limited/inconclusive)